Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect' (opens original article in a new tab)

Novo Nordisk's US EVP discussed the CMS bridge program's impact on Medicare access to obesity treatments, citing uncertainty about patient volume.

• Jamey Millar, Novo Nordisk's US EVP, discussed preparations for the CMS bridge program affecting Medicare access to obesity treatments.
• Millar noted uncertainty about patient volume under the program.